Mangoceuticals
MGRX
19 hedge funds and large institutions have $713K invested in Mangoceuticals in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
129% more capital inflows, than outflows
Capital inflows: $374K | Capital outflows: $163K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 18 → 19 (+1)
0.74% more ownership
Funds ownership: 6.99% → 7.73% (+0.74%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$236K |
| 2 |
Jane Street
New York
|
+$95.1K |
| 3 |
Morgan Stanley
New York
|
+$30.9K |
| 4 |
StoneX Group
New York
|
+$10.7K |
| 5 |
Fortitude Family Office
Scottsdale,
Arizona
|
+$767 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XTX Topco
George Town,
Cayman Islands
|
-$72.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$66.5K |
| 3 |
HRT Financial
New York
|
-$13K |
| 4 |
ACT Advisors
Asheville,
North Carolina
|
-$6.45K |
| 5 |
Goldman Sachs
New York
|
-$4.4K |
MGRX Hedge Fund Activity: Q3 2026 in Review
19 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q3 2026, worth a combined $713K — up 57% from $456K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MGRX positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $236K. The largest seller was XTX Topco, cutting an estimated $72.7K.
- 19 institutional investors held Mangoceuticals (MGRX) as of Q3 2026, up from 18 in Q2 2026.
- Funds reported $713K of Mangoceuticals stock for Q3 2026, up 57% quarter-over-quarter.
- 4 funds opened new Mangoceuticals positions in Q3 2026 and 3 closed out, a net change of +1 holder.
- The largest Mangoceuticals buyer in Q3 2026 was Geode Capital Management, an estimated $236K added.
- The largest Mangoceuticals seller in Q3 2026 was XTX Topco, an estimated $72.7K sold.
Based on aggregated 13F filings for Q3 2026.